Alector (NASDAQ:ALEC) Price Target Raised to $8.00

Alector (NASDAQ:ALEC) had its price target hoisted by HC Wainwright from $5.00 to $8.00 in a research note released on Wednesday, MarketBeat reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Alector’s Q4 2026 earnings at $0.62 EPS, FY2026 earnings at ($0.03) EPS, FY2028 earnings at ($0.82) EPS and FY2030 earnings at ($0.75) EPS.

A number of other research analysts also recently issued reports on ALEC. Weiss Ratings raised Alector from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Morgan Stanley upped their price objective on Alector from $2.00 to $3.00 and gave the stock an “underweight” rating in a research report on Tuesday, October 6th. Finally, UBS Group reaffirmed a “neutral” rating and set a $1.50 price objective on shares of Alector in a research note on Tuesday, October 6th. Three investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $4.00.

Alector Trading Down 3.7%

NASDAQ ALEC opened at $1.84 on Wednesday. The stock has a 50-day simple moving average of $2.11 and a two-hundred day simple moving average of $2.03. Alector has a fifty-two week low of $1.09 and a fifty-two week high of $3.33. The company has a current ratio of 5.26, a quick ratio of 5.26 and a debt-to-equity ratio of 0.80.

Alector (NASDAQ:ALEC) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.02. The business had revenue of $3.32 million during the quarter, compared to analysts’ expectations of $1.71 million. Alector had a negative return on equity of 531.03% and a negative net margin of 850.13%. As a group, equities research analysts forecast that Alector will post -0.47 earnings per share for the current year.

Insider Transactions at Alector

In other news, CFO Neil Berkley sold 29,251 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $2.66, for a total transaction of $77,807.66. Following the sale, the chief financial officer directly owned 350,649 shares in the company, valued at $932,726.34. This trade represents a 7.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Arnon Rosenthal sold 72,606 shares of Alector stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $2.66, for a total value of $193,131.96. Following the completion of the transaction, the chief executive officer owned 2,294,600 shares of the company’s stock, valued at approximately $6,103,636. This represents a 3.07% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 111,303 shares of company stock valued at $295,633. Insiders own 8.30% of the company’s stock.

Hedge Funds Weigh In On Alector

A number of hedge funds have recently bought and sold shares of the business. Diversified Trust Co grew its holdings in Alector by 83.6% in the first quarter. Diversified Trust Co now owns 25,895 shares of the company’s stock valued at $56,000 after purchasing an additional 11,793 shares during the period. The Manufacturers Life Insurance Company acquired a new position in shares of Alector during the 2nd quarter worth approximately $39,000. Bank of New York Mellon Corp raised its stake in shares of Alector by 15.8% during the 1st quarter. Bank of New York Mellon Corp now owns 252,297 shares of the company’s stock worth $542,000 after buying an additional 34,435 shares during the period. Sei Investments Co. raised its stake in shares of Alector by 218.9% during the 1st quarter. Sei Investments Co. now owns 53,846 shares of the company’s stock worth $116,000 after buying an additional 36,962 shares during the period. Finally, Hsbc Holdings PLC purchased a new position in shares of Alector during the 2nd quarter valued at approximately $98,000. Hedge funds and other institutional investors own 85.83% of the company’s stock.

Alector News Roundup

Here are the key news stories impacting Alector this week:

• Positive Sentiment: Premium-priced financing signals investor support. Alector priced an underwritten offering of 36.6 million shares at $2.05 each, approximately 7.3% above the October 15 closing price. Participation from new and existing investors—including TCGX, BVF Partners, ADAR1 Capital Management and Deep Track Capital—helped support the stock. Alector Announces Pricing of Underwritten Offering
• Positive Sentiment: Fresh capital extends Alector’s funding runway. The company expects gross proceeds of approximately $75 million, which it plans to use for research and development, manufacturing, working capital and potential strategic transactions related to its neurodegenerative disease pipeline. The offering is expected to close around October 19, subject to customary conditions. Alector Announces $75 Million Common Stock Offering
• Positive Sentiment: HC Wainwright raised its earnings outlook and maintained a Buy rating. The analyst lifted its FY2026 EPS forecast to a loss of $0.03 from a loss of $0.93, increased estimates for FY2028 and FY2030, and kept an $8 price target—well above recent trading levels. The firm also projects positive fourth-quarter 2026 EPS of $0.62. HC Wainwright Forecasts Strong Price Appreciation for Alector
• Negative Sentiment: Share dilution remains the key drawback. Issuing 36.6 million new shares is sizable relative to Alector’s roughly $205 million market capitalization and will reduce existing shareholders’ ownership percentage. The company also remains unprofitable, so investors will continue to focus on clinical progress and how efficiently the new capital is deployed.

About Alector

Alector, Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company’s approach, known as immuno-neurology, seeks to use the immune system to protect brain health and address biological mechanisms involved in conditions such as Alzheimer’s disease, frontotemporal dementia and Parkinson’s disease.

Alector’s pipeline includes latozinemab, an antibody designed to increase levels of progranulin, a protein associated with the health and function of brain cells.